Adding injectable radioactive therapy (PSMA) in treatment of early metastatic prostate cancer
Phase 2
- Conditions
- Health Condition 1: C61- Malignant neoplasm of prostate
- Registration Number
- CTRI/2024/05/068111
- Lead Sponsor
- JIPMER Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Histologically proven adenocarcinoma prostate
Life expectancy of greater than 9 months and ECOG zero to two
Adequate organ function
Hormone sensitive
PSMA positive lesions in 68Ga PSMA PET/CT
Exclusion Criteria
Prior therapy with agents other than ADT
Prior bone pain palliation radionuclide therapy
Known hypersensitivity to study therapy
Known Sjogren syndrome
Concurrent serious medical conditions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method